Factors associated with prognosis and staging of intrahepatic cholangiocarcinoma

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but aggressive primary liver cancer with a poor prognosis. A number of established clinical and pathologic factors correlate with prognosis, and this is reflected in the American Joint Committee on Cancer (AJCC) 8th Edition staging manual. Researchers have identified areas for improvement in staging and prognostication of ICC using more nuanced tools, including serum biomarkers, molecular profiling, immunophenotyping, and multimodal prognostic scoring systems. These data have led to proposals of novel staging systems that attempt to improve the correlation between stage and prognosis. More accurate staging tools may aid in treatment decisions that are tailored to each individual patient, to maximize therapy for individuals most likely to benefit and to avoid unnecessary toxicity and decision regret in those for whom aggressive treatment is unlikely to alter outcomes. Artificial intelligence and machine learning may help researchers develop new models that predict outcomes with more accuracy and precision.

Keywords

Intrahepatic cholangiocarcinoma / biliary tract cancer / staging / prognosis / predictive models / machine learning

References

[1] Mavros MN,Alexiou VG.Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis.JAMA Surg2014;149:565-74

[2] Ruff SM.Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies.Front Oncol2024;14:1321683 PMCID:PMC10853998

[3] NCCN guidelines version: biliary tract cancers. National comprehensive cancer network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf [Last accessed on 8 Jul 2024]

[4] Primrose JN,Palmer DH.Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.Lancet Oncol2019;20:663-73

[5] Kawashima J,Shen F.Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma.J Gastrointest Surg2024;28:18-25

[6] Oh DY,Qin S.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.NEJM Evid2022;1:EVIDoa2200015

[7] Amin MB,American Cancer Society. AJCC cancer staging manual. 8th ed. Berlin: Springer; 2017.

[8] Zhang XF,He J.Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma.HPB2021;23:1456-66

[9] Maithel SK,Kamel I,Thomas M.Multidisciplinary approaches to intrahepatic cholangiocarcinoma.Cancer2013;119:3929-42

[10] Thinkhamrop K,Chamadol N,Phimha S.Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk population.Sci Rep2022;12:13513 PMCID:PMC9357059

[11] Li Q,Su J.Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study.BMC Cancer2022;22:329 PMCID:PMC8962079

[12] Zhang XF,Bagante F.Implications of intrahepatic cholangiocarcinoma etiology on recurrence and prognosis after curative-intent resection: a multi-institutional study.World J Surg2018;42:849-57

[13] Zhu Y,Cai F,Liu F.Prognostic risk factors associated with recurrence and metastasis after radical resection in patients with hepatolithiasis complicated by intrahepatic cholangiocarcinoma.Cell Biochem Biophys2015;73:455-60

[14] Xu XB,Yang HJ.Isolated anti-HBc is an independent risk factor for tumor recurrence in intrahepatic cholangiocarcinoma after curative resection.Hepatob Pancreat Dis Int2022;21:472-8

[15] Wu ZF,Zhu N.Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.World J Gastroenterol2015;21:935-43 PMCID:PMC4299347

[16] Li Z,Wu Y.HBV infection effects prognosis and activates the immune response in intrahepatic cholangiocarcinoma.Hepatol Commun2024;8:e0360 PMCID:PMC10786594

[17] Taniai T,Yanagaki M.Osteosarcopenia predicts poor prognosis for patients with intrahepatic cholangiocarcinoma after hepatic resection.Surg Today2023;53:82-9

[18] Yugawa K,Kurihara T.Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma.Am J Surg2019;218:952-8

[19] Akgül Ö,Olsen G.Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection.J Surg Oncol2018;118:422-30

[20] Kim JH,Lee TY,Chung H.Effect of age on the prognosis of intrahepatic cholangiocarcinoma.Korean J Intern Med2023;38:39-47 PMCID:PMC9816679

[21] Lurje I,Pavicevic S.Body composition is associated with disease aetiology and prognosis in patients undergoing resection of intrahepatic cholangiocarcinoma.Cancer Med2023;12:17569-80 PMCID:PMC10524050

[22] Merath K,Hyer JM.Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis.Eur J Surg Oncol2019;45:1084-91

[23] Yu Q,Ma W.Postoperative prognosis of non-alcoholic fatty liver disease-associated intrahepatic cholangiocarcinoma: a multi-center propensity score matching analysis.J Gastrointest Surg2023;27:2403-13

[24] Fu K,Wu H,Li X.Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma.Oncol Lett2020;20:265 PMCID:PMC7517629

[25] De Lorenzo S,Mazzotta A.Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role.Cancers2020;12:3182 PMCID:PMC7692633

[26] Fei Y,Wei F.The impact of cirrhosis on the prognosis of intrahepatic cholangiocarcinoma after surgery.Asian J Surg2023;46:1361-3

[27] Zhang JX,Chen Z.Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis.BMC Cancer2020;20:556 PMCID:PMC7296657

[28] Amory B,Laurent A.Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: different survival, similar recurrence: report of a large study on repurposed databases with propensity score matching.Surgery2024;175:413-23

[29] Song P,Nakayama H.Patients’ prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection.Cancer Med2019;8:5862-71 PMCID:PMC6792494

[30] Jung DH,Kim KH.Clinicopathological features and post-resection prognosis of double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma.World J Surg2017;41:825-34

[31] Kaneko S,Tsuchiya K.Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade.Hepatol Res2021;51:902-8

[32] Zhang B,Zhou B.High serum gamma-glutamyl transpeptidase concentration associates with poor postoperative prognosis of patients with hepatitis B virus-associated intrahepatic cholangiocarcinoma.Ann Transl Med2021;9:17 PMCID:PMC7859769

[33] Lu Z,Yi Y.Serum gamma-glutamyl transferase levels affect the prognosis of patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: a propensity score matching study.Int J Surg2017;37:24-8

[34] Association for the Study of the Liver. Electronic address: [e-mail], European association for the study of the liver. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma.J Hepatol2023;79:181-208

[35] Geh D,Sen G.COVID-19 and liver cancer: lost patients and larger tumours.BMJ Open Gastroenterol2022;9:e000794 PMCID:PMC9023844

[36] Turner KM,Kharofa J.A national assessment of T2 staging for intrahepatic cholangiocarcinoma and the poor prognosis associated with multifocality.Ann Surg Oncol2022;29:5094-102

[37] Sohn HJ,Kim JR.Predicting prognosis and evaluating the benefits of adjuvant chemotherapy depending on the tumor location in intrahepatic cholangiocarcinoma: focusing on the involvement of below 2nd bile duct confluence.Ann Surg Treat Res2022;102:248-56 PMCID:PMC9111963

[38] Zhang XF,Chen Q.Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma.Surgery2018;163:1114-20

[39] Spolverato G,Kim Y.The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma.Ann Surg Oncol2015;22:4020-8

[40] Li MX,Li ZY.Impaction of surgical margin status on the survival outcome after surgical resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.J Surg Res2016;203:163-73

[41] Jiang JH,Hu YT.Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.BMJ Open2023;13:e067222 PMCID:PMC10174020

[42] Wu L,Paredes AZ.Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival.World J Surg2019;43:1777-87

[43] Bagante F,Weiss M.Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic Cholangiocarcinoma.Ann Surg Oncol2017;24:2491-501

[44] Tsilimigras DI,Cloyd J.Tumor necrosis impacts prognosis of patients undergoing resection for T1 intrahepatic cholangiocarcinoma.Ann Surg Oncol2022:4326-34

[45] Bartsch F,Baumgart J.Influence of lymphangio (L), vascular (V), and perineural (Pn) invasion on recurrence and survival of resected intrahepatic cholangiocarcinoma.J Clin Med2021;10:2426 PMCID:PMC8199279

[46] Shao C,Shi J,Qiu Y.Histological classification of microvascular invasion to predict prognosis in intrahepatic cholangiocarcinoma.Int J Clin Exp Pathol2017;10:7674-81 PMCID:PMC6965212

[47] Kosaka H,Ueno M.Impact of trinal histological glandular differentiation grade on the prognosis of patients with intrahepatic cholangiocarcinoma: a multicenter retrospective study.J Gastrointest Surg2023;27:2780-6

[48] Bednarsch J,Czigany Z.The presence of small nerve fibers in the tumor microenvironment as predictive biomarker of oncological outcome following partial hepatectomy for intrahepatic cholangiocarcinoma.Cancers2021;13:3661 PMCID:PMC8345152

[49] Wang T,Yang X,Zhang M.Clinical features of sarcomatoid change in patients with intrahepatic cholangiocarcinoma and prognosis after surgical liver resection: a propensity score matching analysis.J Surg Oncol2020;121:524-37

[50] Sha M,Wang X.Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma.BMC Cancer2019;19:208 PMCID:PMC6407234

[51] Türkoğlu MA,Sugiura T.The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: a clinicopathologic and immunohistochemical study.Surgery2016;160:683-90

[52] Xin HY,Sun RQ.Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.J Gastroenterol2024;59:411-23

[53] Wang J,Peng H.The influence of the extent of lymph node metastasis on the prognosis for patients with intrahepatic cholangiocarcinoma.Ann Surg Treat Res2023;104:258-68 PMCID:PMC10172033

[54] Bartsch F,Müller L.Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma.BMC Surg2020;20:75 PMCID:PMC7161232

[55] Zhang XF,Dong DH.Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis.Ann Surg2021;274:e1187-95

[56] Li F,Jiang L.Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.Front Oncol2022;12:957792 PMCID:PMC9552707

[57] Zhu J,Li H.Adequate lymph node dissection is essential for accurate nodal staging in intrahepatic cholangiocarcinoma: a population-based study.Cancer Med2023;12:8184-98 PMCID:PMC10134328

[58] Zhang R,Chen C.The optimal number of examined lymph nodes for accurate staging of intrahepatic cholangiocarcinoma: a multi-institutional analysis using the nodal staging score model.Eur J Surg Oncol2023;49:1429-35

[59] Spolverato G,Weiss M.Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma.J Surg Oncol2017;115:696-703

[60] Lozada ME,Jin W.CS-iCCA, a new clinically based staging system for intrahepatic cholangiocarcinoma: establishment and external validation.Am J Gastroenterol2023;118:2173-83 PMCID:PMC10739641

[61] Shaikh CF,Moazzam Z.Predicting overall and recurrence-free survival in patients with intrahepatic cholangiocarcinoma using the MEGNA score: a multi-institutional analysis.J Surg Oncol2023;127:73-80

[62] Wang C,Danzeng A.Anatomical resection improved the outcome of intrahepatic cholangiocarcinoma: a propensity score matching analysis of a retrospective cohort.J Oncol2022;2022:4446243 PMCID:PMC9626204

[63] Langella S,Ossola P.Recurrence after curative resection for intrahepatic cholangiocarcinoma: how to predict the chance of repeat hepatectomy?.J Clin Med2021;10:2820 PMCID:PMC8269164

[64] Zhang XF,Chakedis J.Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy.J Gastrointest Surg2017;21:1841-50

[65] Ratti F,Clocchiatti L.Minimally invasive approach provides oncological benefit in patients with high risk of very early recurrence (VER) after surgery for intrahepatic cholangiocarcinoma (iCCA).Ann Surg Oncol2024;31:2557-67

[66] Tsilimigras DI,Wu L.Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches.JAMA Surg2020;155:823-31 PMCID:PMC7344787

[67] Carpenter EL,Adams AM.Modern trends in minimally invasive versus open hepatectomy for colorectal liver metastasis: an analysis of ACS-NSQIP.Surg Endosc2023;37:5591-602

[68] Vreeland TJ,Ozair A.SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM).Surg Endosc2023;37:2508-16

[69] Martin SP,Wach MM.Laparoscopic approach to intrahepatic cholangiocarcinoma is associated with an exacerbation of inadequate nodal staging.Ann Surg Oncol2019;26:1851-7 PMCID:PMC8132107

[70] Yamada T,Okamura K.Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma.J Gastroenterol Hepatol2018:1626-33

[71] Bergquist JR,Storlie CB.Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: a national cohort analysis.J Surg Oncol2016;114:475-82 PMCID:PMC6038702

[72] He C,Song Y.Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma.J Cancer2018;9:3117-28 PMCID:PMC6134824

[73] Mantovani A,Sica A.Cancer-related inflammation.Nature2008;454:436-44

[74] Choi WJ,Gravely A.Preoperative neutrophil-to-lymphocyte ratio is prognostic for early recurrence after curative intrahepatic cholangiocarcinoma resection.Ann Hepatobiliary Pancreat Surg2023;27:158-65 PMCID:PMC10201063

[75] Omichi K,Yamashita S.Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma.Surgery2017;162:752-65

[76] Chen Q,Li XD.The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy.Tumour Biol2015;36:5283-9

[77] Huh G,Chun JW.High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.BMC Cancer2020;20:907 PMCID:PMC7510111

[78] Chen Q,Yin D.Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma.Medicine2015;94:e574 PMCID:PMC4554024

[79] Tsilimigras DI,Mehta R.The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis.HPB2020;22:1667-74

[80] Liu H,Hu F.Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection.World J Surg Oncol2021;19:218 PMCID:PMC8293519

[81] Zhu J,Liu C.Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: a multicenter study.Front Immunol2023;14:1165510 PMCID:PMC10102611

[82] Yoh T,Kasai Y.Serum nardilysin, a surrogate marker for epithelial-mesenchymal transition, predicts prognosis of intrahepatic cholangiocarcinoma after surgical resection.Clin Cancer Res2019;25:619-28

[83] Jiang S,Huang B.Longitudinal change of circulating tumour cell count and its relation to prognosis in advanced intrahepatic cholangiocarcinoma patients.Scand J Clin Lab Invest2023;83:234-40

[84] Zhu AX,Kim Y.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Ann Surg Oncol2014;21:3827-34 PMCID:PMC4324507

[85] Andraus W,de Meira Junior JD.Molecular profile of intrahepatic cholangiocarcinoma.Int J Mol Sci2023;25:461 PMCID:PMC10778975

[86] Weinberg BA,Lindberg MR.Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.J Gastrointest Oncol2019;10:652-62 PMCID:PMC6657312

[87] Tomczak A,Dill MT.Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.Br J Cancer2022;127:1701-8 PMCID:PMC9390961

[88] Robertson S,Dodson R.The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.Hum Pathol2013;44:2768-73 PMCID:PMC3838441

[89] Peng J,Li M.Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis.Open Life Sci2023;18:20220652 PMCID:PMC10358752

[90] Guo C,Yu Y.TP53/KRAS Co-mutations create divergent prognosis signatures in intrahepatic cholangiocarcinoma.Front Genet2022;13:844800 PMCID:PMC8990229

[91] Xin HY,Zou JX.Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma.JAMA Netw Open2023;6:e231476 PMCID:PMC9984974

[92] Subbiah V,Gasal E,Wainberg ZA.Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer - Authors’ reply.Lancet Oncol2020;21:e516

[93] Boerner T,Pak LM.Genetic determinants of outcome in intrahepatic cholangiocarcinoma.Hepatology2021;74:1429-44 PMCID:PMC8713028

[94] Toshida K,Yugawa K.Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection.Hepatol Res2023;53:432-9

[95] Abou-Alfa GK,Schultz N.Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma.Target Oncol2022;17:517-27 PMCID:PMC9512879

[96] Bekaii-Saab TS,Van Cutsem E.FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Future Oncol2020;16:2385-99 PMCID:PMC9892961

[97] Chen L,Han Z.The impact of decreased expression of SVEP1 on abnormal neovascularization and poor prognosis in patients with intrahepatic cholangiocarcinoma.Front Genet2022;13:1127753 PMCID:PMC9870246

[98] Tang Z,Zhang Q.Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.Clin Epigenetics2023;15:13 PMCID:PMC9875497

[99] Wu L,Ke RS.Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma.Clin Res Hepatol Gastroenterol2022;46:101999

[100] Bi C,Rong W.High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.BMC Cancer2019;19:213 PMCID:PMC6408801

[101] Yao X,Wang M.Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma.Acta Biochim Biophys Sin2022;54:1376-85 PMCID:PMC9828311

[102] Sarcognato S,Fabris L.Ferroptosis in intrahepatic cholangiocarcinoma: IDH1(105GGT) single nucleotide polymorphism is associated with its activation and better prognosis.Front Med2022;9:886229 PMCID:PMC9304620

[103] Ren H,Zhang C.A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis.Cancer Cell Int2024;24:92 PMCID:PMC10908169

[104] Marabelle A,Ascierto PA.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II keynote-158 study.J Clin Oncol2020;38:1-10

[105] Song JP,Chen Q.High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma.World J Clin Cases2022;10:790-801 PMCID:PMC8790456

[106] Deng M,Fu X.Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.Cancer Cell Int2021;21:371 PMCID:PMC8273972

[107] Tian L,Ma L.PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.World J Surg Oncol2020;18:303 PMCID:PMC7686719

[108] Dong Z,Shen W,Yang J.Expression of programmed death ligand 1 is associated with the prognosis of intrahepatic cholangiocarcinoma.Dig Dis Sci2020;65:480-8

[109] Zhu Y,Zhang Y.Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8⁺ T-cell immune responses.Cancer Manag Res2018;10:4113-23 PMCID:PMC6174308

[110] Cheng R,Zhou H,Du Q.B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma.J Pathol Microbiol Immunol2018;126:396-402

[111] Miyazaki K,Imura S.Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8⁺ tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma.Surg Today2021;51:1985-95

[112] Yang H,Li W.SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.J Transl Med2022;20:140 PMCID:PMC8939174

[113] Xu L,Long J,Yang H.Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.Front Oncol2022;12:967982 PMCID:PMC9497456

[114] Sun D,Dong P.CD86⁺/CD206⁺ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma.PeerJ2020;8:e8458 PMCID:PMC6982414

[115] Oishi K,Baba S,Konno H.Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma.Surg Today2015;45:715-22

[116] Xu Y,Zhou Y.Using immunovascular characteristics to predict very early recurrence and prognosis of resectable intrahepatic cholangiocarcinoma.BMC Cancer2023;23:1009 PMCID:PMC10588260

[117] Ding GY,Yun JP.Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.J Hepatol2022;76:608-18

[118] Doi N,Fuse M,Shimada K.Correlation of vein-rich tumor microenvironment of intrahepatic cholangiocarcinoma with tertiary lymphoid structures and patient outcome.Mod Pathol2024;37:100401

[119] Hu ZQ,Luo CB.Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection.Cancer Cell Int2020;20:582 PMCID:PMC7716503

[120] Fukuda Y,Eguchi H.Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.Cancer Sci2020;111:323-33 PMCID:PMC7004525

[121] Zhu C,Zhu K.Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma.JHEP Rep2023;5:100762 PMCID:PMC10285646

[122] Thongchot S,Ferraresi A.Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway.Mol Carcinog2018;57:1735-50

[123] Thongchot S,Ferraresi A.Cancer-associated fibroblast-derived IL-6 determines unfavorable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse.Cancers2021;13:2134 PMCID:PMC8124468

[124] Thongchot S,Vidoni C.Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis.Cancer Lett2024;582:216589

[125] Liu Z,Xu H.Computational recognition and clinical verification of TGF-β-derived mirna signature with potential implications in prognosis and immunotherapy of intrahepatic cholangiocarcinoma.Front Oncol2021;11:757919 PMCID:PMC8573406

[126] Zeng TM,Yuan ZG,Song YJ.Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.Front Immunol2022;13:943066 PMCID:PMC9501891

[127] Yue Y,An D.Exploring the role of tumor stemness and the potential of stemness-related risk model in the prognosis of intrahepatic cholangiocarcinoma.Front Genet2022;13:1089405 PMCID:PMC9877308

[128] Tian MX,Qu WF.Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.Cancer Immunol Immun2019;68:1369-78 PMCID:PMC11028083

[129] Zhang LT,Chen XM,Tong GL.IL23R as an indicator of immune infiltration and poor prognosis in intrahepatic cholangiocarcinoma: a bioinformatics analysis.Transl Cancer Res2023;12:2461-76 PMCID:PMC10643953

[130] Liang J,Huang XQ.A myeloid signature-based nomogram predicts the postoperative recurrence of intrahepatic cholangiocarcinoma.Front Mol Biosci2021;8:742953 PMCID:PMC8548627

[131] Hwang JA,Lee JE,Choi SY.LI-RADS Category on MRI is associated with recurrence of intrahepatic cholangiocarcinoma after surgery: a multicenter study.J Magn Reson Imaging2023;57:930-8

[132] Nishioka E,Kozuki R.Comparison of conventional imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with intrahepatic cholangiocarcinoma.Diagnostics2022;12:2889 PMCID:PMC9689116

[133] Lin Y,Song G.The influence of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr2022;11:684-95 PMCID:PMC9577996

[134] Ikeno Y,Iwaisako K.Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by ¹⁸F-FDG-PET is associated with the KRAS mutation status and prognosis.J Transl Med2018;16:95 PMCID:PMC5896043

[135] Brunese MC,Fusco R.Update on the applications of radiomics in diagnosis, staging, and recurrence of intrahepatic cholangiocarcinoma.Diagnostics2023;13:1488 PMCID:PMC10137417

[136] Wakiya T,Kimura N.CT-based deep learning enables early postoperative recurrence prediction for intrahepatic cholangiocarcinoma.Sci Rep2022;12:8428 PMCID:PMC9120508

[137] Chen B,Li J.Predicting very early recurrence in intrahepatic cholangiocarcinoma after curative hepatectomy using machine learning radiomics based on CECT: a multi-institutional study.Comput Biol Med2023;167:107612

[138] Bo Z,Yang Y.Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: a multicentre cohort study.Eur J Nucl Med Mol Imaging2023;50:2501-13

[139] Jolissaint JS,Soares KC.Machine learning radiomics can predict early liver recurrence after resection of intrahepatic cholangiocarcinoma.HPB2022;24:1341-50 PMCID:PMC9355916

[140] Hao X,Hu X.A radiomics-based approach for predicting early recurrence in intrahepatic cholangiocarcinoma after surgical resection: a multicenter study.Annu Int Conf IEEE Eng Med Biol Soc2021;2021:3659-62

[141] Zhang J,Zhang X.Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers.ESMO Open2020;5:e000910 PMCID:PMC7689588

[142] Xu Y,Yang Y.A CT-based radiomics approach to predict intra-tumoral tertiary lymphoid structures and recurrence of intrahepatic cholangiocarcinoma.Insights Imaging2023;14:173 PMCID:PMC10577112

[143] Wang J,Shen J.Development and external validation of a prognosis model to predict outcomes after curative resection of early-stage intrahepatic cholangiocarcinoma.Front Surg2023;10:1102871 PMCID:PMC10030709

[144] Li Q,Chen C.A nomogram model to predict early recurrence of patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy guidance: a multi-institutional analysis.Front Oncol2022;12:896764 PMCID:PMC9259984

[145] Tsilimigras DI,Guglielmi A.Recurrent intrahepatic cholangiocarcinoma: a 10-point score to predict post-recurrence survival and guide treatment of recurrence.Ann Surg Oncol2024;31:4427-35

[146] Nassar A,Sindayigaya R.Factors of early recurrence after resection for intrahepatic cholangiocarcinoma.World J Surg2022;46:2459-67

[147] Choi WJ,Claasen MPAW.Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection.Ann Surg Oncol2022:4337-53

[148] Zhang XF,Bagante F.Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent.Br J Surg2018;105:848-56

[149] Akaoka M,Furukawa K.Analysis of preoperative risk factors for early recurrence in patients after hepatic resection for intrahepatic cholangiocarcinoma.Am Surg2024;90:1148-55

[150] Li H,Qiu H.Tumor burden score stratifies prognosis of patients with intrahepatic cholangiocarcinoma after hepatic resection: a retrospective, multi-institutional study.Front Oncol2022;12:829407 PMCID:PMC8940520

[151] Tsilimigras DI,Hyer JM.Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.Br J Surg2020;107:854-64

[152] Lv Y,He P.A novel model for predicting the prognosis of postoperative intrahepatic cholangiocarcinoma patients.Sci Rep2023;13:19267 PMCID:PMC10630332

[153] Alaimo L,Endo Y.Long-term recurrence-free and overall survival differ based on common, proliferative, and inflammatory subtypes after resection of intrahepatic cholangiocarcinoma.Ann Surg Oncol2023;30:1392-403

[154] Alaimo L,Brown ZJ.Application of hazard function to investigate recurrence of intrahepatic cholangiocarcinoma after curative-intent liver resection: a novel approach to characterize recurrence.Ann Surg Oncol2023;30:1340-9

[155] Moro A,Farooq A.Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: a preoperative vs postoperative perspective.J Surg Oncol2019;120:946-55

[156] Alaimo L,Moazzam Z.Development and validation of a machine-learning model to predict early recurrence of intrahepatic cholangiocarcinoma.Ann Surg Oncol2023;30:5406-15

[157] Buettner S,van Vugt JLA.Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma.J Surg Oncol2017;116:1085-95

[158] Alaimo L.ASO author reflections: use of machine learning to predict early recurrence after resection of intrahepatic cholangiocarcinoma.Ann Surg Oncol2023;30:5416-7

[159] Bagante F,Cucchetti A.Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: a regret-based decision curves analysis.Surgery2016;160:106-17

[160] Wilson A,Yahanda A,Ronnekleiv-Kelly S.Factors associated with decisional regret among patients undergoing major thoracic and abdominal operations.Surgery2017;161:1058-66

[161] Kodama K,Kosaka M.Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.J Gastroenterol2022;57:676-83

[162] Yang Y,Zhao H,Huang F.A survey of recent methods for addressing AI fairness and bias in biomedicine.J Biomed Inform2024;154:104646 PMCID:PMC11129918

[163] Giuliano AE,Edge SB.Breast cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual.CA Cancer J Clin2017;67:290-303